Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

This study has been completed.
Information provided by:
UCB Pharma Identifier:
First received: August 24, 2005
Last updated: September 19, 2014
Last verified: July 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2006
  Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):